Kimberly-Clark said on Wednesday that its chief financial officer, Nelson Urdaneta, will take on the role of finance chief of the combined company after it completes its planned $40 billion acquisition of Kenvue, the maker of Tylenol.
Read Also – Oncoclínicas ends negotiations with Porto and Fleury, considers new potential deals
The deal, which was announced in November, is expected to close in the second half of 2026, subject to regulatory approvals.
- The new entity will operate through four business segments: North America, Asia Pacific Focus Markets, Europe–Middle East–Africa (EMEA), and Enterprise Markets, each led by regional presidents.
- Russ Torres will serve as group president and chief operating officer, alongside other senior leadership roles including chief growth officer, chief R&D officer, and chief supply chain officer.
- Kimberly-Clark said more than 30 integration teams are working on identifying opportunities to grow the business and reduce costs.
- The acquisition of the former Johnson & Johnson consumer health unit Kimberly-Clark’s largest-ever deal is expected to create a global health and wellness leader with around $32 billion in annual sales, expanding its presence in consumer health and personal care.
- Upon closing, Mike Hsu is set to become both CEO and chairman of the combined company, as previously stated at the time of the deal.
